The role of B cells in bone turnover in rheumatoid arthritis

Recent research has focused on the link between the immune and skeletal systems leading to the emergence of a new discipline named osteoimmunology, which incorporates the complex interactions and overlap between the two systems. The effect of B lymphocytes on bone metabolism is still poorly understood, although recent evidence suggests that B cells may be implicated in the pathogenesis of bone loss in patients with rheumatoid arthritis. Mature B cells have the potential to both inhibit and stimulate osteoclastogenesis via the secretion of specific cytokines; they have the ability to produce RANKL, a pro-osteoclastogenic cytokine, osteoprotegerin, an antiosteoclastogenic cytokine, and TGF-β, a cytokine that has the ability to both induce and inhibit osteoclast formation. It is, therefore, not surprising that the existing evidence from both in vitro and in vivo studies is inconsistent. This review critically examines the role of B lymphocytes and key cytokines in the regulation of osteoblasto- and osteoclastogenesis in rheumatoid arthritis.

KEYWORDS: B-cell depletion B lymphocytes bone turnover osteoclastogenesis osteoporosis rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease characterized by symmetrical polyarthritis, joint destruction and extra-articular manifestations that can affect different organ systems including the blood, skin, eyes, kidneys, heart and lungs. RA affects approximately 0.5–1% of the adult population worldwide [1]. The incidence of RA in England alone is 26,000 new cases per year, while its prevalence is believed to be more than 690,000 patients, resulting in a total annual cost of almost GBP£8 billion [2]. RA is characterized by increased morbidity and mortality with considerable reduction in quality of life. While there has been progress in defining the etiology and pathogenesis of RA, these are still incompletely understood. There is synovial inflammation, subsequent pannus formation and intra-articular bone erosions, which result in structural damage, and it is this joint damage that is the major reason for disability in RA patients. In addition, the disease can affect the whole musculoskeletal system including bones, cartilage, ligaments and tendons. There is both localized, periarticular bone loss, as well as generalized bone loss. Osteoporosis is one of the leading morbidities of RA and approximately one third of women with RA will develop a fracture within 5 years of their diagnosis [3]. These data clearly show that bone loss in RA is a significant public health issue; this review will focus on the importance of B cells in RA and their effects on the associated bone loss.

B lymphocytes are typically characterized by their ability to produce antibodies, including autoantibodies. Since the discovery of rheumatoid factor (RF) and autoantibodies against citrullinated peptides, the role of B lymphocytes in RA has become more established and a number of treatments have been developed to specifically target B cells. TNF-α-blocking agents were the first biological therapies to be approved for treating RA, however, it is estimated that between 20 and 40% of patients fail to achieve a 20% improvement in the American College of Rheumatology criteria. In addition, many patients lose response over time (secondary failure) and others develop side effects [4]. The relative success of specifically targeting TNF-α focused research into other components of the immune system in RA. Rituximab (RTX) is the first B-cell-targeted treatment originally used for the treatment of hematological malignancies such as lymphoma and leukemia. RTX is a chimeric monoclonal antibody directed against the CD20 molecule found on the surface of B cells. It depletes a large proportion of the B-cell population with the exception of pro-B cells and mature plasma cells. RTX has proven to be highly successful and has renewed the interest in the role of B cells in RA [5]. Recent investigations have provided a great deal of evidence for a complex interaction between the immune and skeletal systems in physiological and pathological conditions. Results have shown
that a number of cell surface receptors, cytokines and signaling pathways serve a critical role in both systems. In RA, the immune disturbance results in abnormal bone remodeling leading to bone loss. It is becoming clear that immune cells influence bone remodeling and vice versa.

The interaction between immune progenitor cells and bone cells is facilitated by their proximity in the bone marrow, where both osteoclastogenesis and hematopoiesis take place. The role of the immune system, especially T cells, in inflammatory bone resorption and osteoclastogenesis is well established [6]. In addition to the indirect effects on bone turnover through the production of inflammatory cytokines that modulate osteoclastogenesis, T cells may also regulate bone turnover through direct cell–cell interaction with bone cells [7,8]. On the other hand, bone cells may influence the immune responses, as well as accentuate bone turnover by affecting T-cell activity through their ability to secrete different cytokines. Osteoclasts express MHC class II molecules on their surface; they also activate CD40/CD40L signaling, which is essential for T-cell, macrophage and B-cell activation [9]. Additionally, in vitro studies revealed that osteoclasts release abundant T-cell chemottractants and can alter T-cell responses by different mechanisms including: decreasing their development; inhibiting their cytokine production such as TNF-α and IFN-γ; and by regulating their apoptosis [10].

The role of B cells in bone turnover in RA is still controversial. However, recent work by our group has demonstrated decreased bone resorption and increased formation following treatment with RTX, suggesting that B cells may also be important in regulating bone turnover [11]. Other components of the immune system such as cytokines also play a critical role in the pathogenesis of RA-induced bone loss. The most important cytokines involved in the disturbed bone imbalance in RA are RANKL and OPG [12].

**Overview of B cells**

**B-cell development**

B cells are formed in the bone marrow where hematopoietic stem cells differentiate initially through the pro-B, pre-B-cell stage and into immature B cells, which then complete their maturation in the spleen through three developmental stages: transitional Type 1; Type 2; then mature B cells [13]. Mature B cells then differentiate into antibody-secreting plasma cells and memory B cells, also known as effector B cells. B cells are subdivided into two main types; B1 cells are characterized by expressing mainly immunoglobulin M (IgM) and are present in low numbers in the lymph nodes and spleen, and more abundantly in the peritoneal and pleural cavities, while B2 cells are present in the peripheral circulation and the bone marrow [14]. Recent studies also indicate the coexistence of a distinct B-cell subset called B regulatory cells (Bregs), which inhibit the immune response and regulate the functions of the immune system components.

**Regulation of B-cell function**

B-cell regulation in physiological and pathological conditions is a complex mechanism under the influence of many cells. T cells play a major role in the activation of B cells by two mechanisms. The first mechanism is through direct cell-to-cell contact in which the primary signal is the B-cell receptor binding to antigen and then presenting the antigen via MHC class II to the T-cell receptor on the surface of T cells. These in turn provide B cells with the secondary signal via costimulatory binding of CD40L on T cells to CD40 on B cells to complete the B-cell activation [15]. However, it should be noted that the antigen-presenting function of B lymphocytes is thought to be relevant mainly in the late phase of infections and in secondary immune responses, due to the low number of clonogenic antigen-specific B cells that are present in homeostatic conditions [16]. The second mechanism by which T cells regulate B-cell activity is by the release of lymphokines acting as growth factors for B cells [17]. Additionally, many factors contribute to the regulation of B-cell development and activity, summarized in Table 1.

**Regulation of B-cell homeostasis by bone cells**

B lymphopoiesis is maintained by osteoblasts in the bone marrow by their ability to support the differentiation and proliferation of hematopoietic stem cells into all B-cell stages. Culturing murine osteoblasts in vitro with primitive hematopoietic stem cells led to their differentiation into mature B lymphocytes [18]. The authors showed that osteoblasts activated by PTH, stimulated B-cell differentiation by signaling pathways that include VCAM-1, SDF-1 and IL-7. Furthermore, adding cytokines produced by stromal cells of nonosteoblastic origin, such as c-Kit ligand, IL-6 and IL-3, led to myelopoiesis instead of lymphopoiesis. Also, the elimination of osteoblasts in vivo resulted in B-cell depletion [18]. In a different murine model, blockade of
The role of B cells in bone turnover in rheumatoid arthritis

Review

The role of B cells in bone turnover in rheumatoid arthritis

osteoelastic PTH signaling by ablation of the Gs, a class of G proteins that activate phospholipase C and participate in a variety of cellular signaling pathways, led to a marked decrease in the number of B cells in the bone marrow but not other hematopoietic cells [19].

Osteoclast activity is also suggested to have a critical role in B-cell development in the bone marrow. Evidence has been obtained through studies in osteopetrosis. In this genetic condition there is a failure of bone resorption by osteoclasts and increased bone density, however the bone structure is poor and there is a tendency to fracture. Osteopetrosis is also characterized by reduced numbers of B cells, whether this decrease in B-cell number is due to impaired bone marrow architecture and abnormal microenvironment, or if this is a direct effect of the disturbed function of osteoclasts on B cells in the bone marrow is unknown. Reports from the literature suggest that interactions between B-cell precursors and bone marrow stromal cells are essential for B-cell differentiation, but the role of osteoclasts in this process remains controversial [20]. Recently, a mouse model injected with zoledronic acid, an antiresorptive agent, to artificially induce osteopetrosis, was used to clarify the link between osteoclastic activity and B-cell development. Zoledronic acid led to suppression of osteoclastogenesis and a marked reduction in B-cell numbers. The authors concluded that osteoclasts can modulate B-cell development in the bone marrow by controlling the bone microenvironment and the osteoblastic activity but they could not rule out that osteoclasts may directly affect B lymphopoiesis [21].

Role of B cells in rheumatoid arthritis

B cells have multiple roles in the pathogenesis of RA; they secrete autoantibodies such as RF and the highly specific anticyclic citrullinated peptides antibodies (ACPA). RFs are antibodies directed against the Fc portion of IgG, and along with ACPA they are thought to play a major role in the perpetuation of immune complexes, which are suggested to be the main trigger for RA pathology. Additionally, B cells can process and present immune complexes and consequently activate complement thus contributing to autoimmune responses [22]. B cells are also able to secrete different proinflammatory cytokines and promote differentiation of follicular dendritic cells in secondary lymphoid organs [23]. In RA, effector B cells, for example, secrete TNF-α, IL-6, IL-12 and IFN-γ [24,25]. TNF-α

| Table 1. Factors affecting B-cell development. |
|---|---|---|
| Factor | Effect | Ref. |
| BAFF (BLyS) | Protein belonging to the TNF superfamily that activates B-cell differentiation; concentration was found to be higher in RA patients compared to controls | [81] |
| APRIL | Activator of B-cell differentiation that has been found to be a higher concentration in RA patients compared to controls | [81] |
| Btk | Activator of B-cell differentiation; its absence led to impaired B-cell responses and reduced immunoglobulin levels | [82] |
| RANK | Essential for B-cell maturation and development; its deficiency in mice resulted in failed B-cell maturation | [83] |
| IL-7 | Essential cytokine for B-cell development; its deficiency leads to blockade of the transition between the Ly6D− and the Ly6D+ stages of B-cell development | [84] |
| Neurotransmitter receptors (dopamine receptor 2 and acetylcholine receptor) | Essential components for B-cell development and were found to be overexpressed in B cells of RA patients compared to healthy individuals | [85] |
| EBF-1 | Protein needed for early B-cell development that determines the subset fate of early B cells; its deficiency led to arrested B-cell development and maturation | [86] |
| PAX5 | Essential protein for B-cell development; its deficiency led to arrested B-cell development and maturation | [73] |
| PU.1 | A member of the ETS domain transcription factors that regulate the development of B lineage cells; its deficiency impedes B-cell proliferation | [70] |
| Ikzf1 | Transcription factor encoded by the Ikaros gene (Ikzf1); its deficiency led to a complete failure of B-cell development | [87] |

BLyS: B-lymphocyte stimulator; RA: Rheumatoid arthritis.
plays a critical role in the pathogenesis of RA and its inhibition is currently one of the most successful treatments available for this disease. TNF-α has a wide variety of functions including complement activation and stimulation of synovial fibroblasts and macrophages to secrete proinflammatory cytokines such as IL-6, prostaglandin E2 (PGE2) and matrix metalloproteinases (MMPs) inducing inflammation, cartilage and bone damage, in addition to TGF-β, granulocyte/monocyte-colony stimulating factor (GM-CSF) and other growth factors that induce neovascularization and promote pannus formation characteristic of RA [26-27]. IL-6, another major proinflammatory mediator secreted by many cells including B cells, has a pivotal role in RA. IL-6 shares many effects with TNF-α, including stimulation of neovascularization, promotion of acute phase response, infiltration of inflammatory cells, synovial hyperplasia and damage to cartilage and bone [28]. B cells also produce IL-12, which stimulates the release of IFN-γ by T lymphocytes and natural killer cells, and activates the T-cell immune response, leading to cellular infiltration, induction of inflammation, as well as cartilage and bone destruction [29]. IL-12 levels in serum and in synovium correlate with disease activity in RA revealing the definite role of this mediator in RA pathology [30]. On the other hand, IFN-γ is found to have a dual action on chronic inflammation as it is capable of inducing both chronic inflammation and regulating immune responses [31].

Interestingly, B cells can also secrete anti-inflammatory mediators such as IL-4 and IL-13. IL-4 inhibits the activity of proinflammatory TNF-α, IL-1, IL-11 and IL-6, in addition to upregulating the inhibitory mediator IL-1 receptor antagonist in RA [32]. IL-13, similar to IL-4, is capable of suppressing the inflammation in RA [33].

Recently, a new subtype of regulatory B lymphocytes known as Bregs has been reported to regulate the immune system by producing the inhibitory cytokine IL-10. IL-10, also known as human cytokine synthesis inhibitory factor, has pleiotropic effects in immune-regulation and inflammation. It downregulates the proliferative responses and proinflammatory cytokine production by T helper cells, MHC class II antigen expression and costimulatory molecules on macrophages. Moreover Bregs can promote differentiation of T cells into regulatory IL-10-producing T cells and hence permit vigorous immune suppression. Despite these anti-inflammatory effects, IL-10 has also been found to be an activator of B-cell proliferation and antibody production. Moreover, Bregs were found to have other potential inhibitory mechanisms including secretion of the inhibitory cytokine TGF-β, interactions with Tregs and the production of regulatory antibodies [34].

Pathogenesis of bone loss in RA
RA predisposes to both localized and generalized bone loss and increased fracture risk. This bone loss is multifactorial. Some of the drugs used to treat the condition can themselves cause bone loss, such as glucocorticoids. Corticosteroids have been considered to be the cornerstone of the treatment of RA and most of the autoimmune diseases. Long-term use of corticosteroids is an established cause of generalized bone loss in RA. Nowadays, corticosteroid use has been minimized with the tendency for more aggressive use of disease-modifying drugs and the development of biological therapy. RA can be significantly disabling, leading to marked reduction in mobility and even loss of the patient’s ability to feed themselves, which results in disuse atrophy of the muscles and a consequent reduction in bone mass. Muscle atrophy and joint destruction will also increase falls risk. Inflammation and autoimmunity are the main mechanisms of osteoporosis in RA. Chronic systemic inflammation leads to generalized osteoporosis and localized inflammation with regional osteoporosis [35]. It was, therefore, presumed that treating inflammation would be sufficient to stop bone loss in RA, but this view is now thought to be too simplistic.

Role of cytokines
It has been well established that RA leads to increased bone resorption, but it has more recently been demonstrated that there is also substantially reduced bone formation [36]. The increased bone resorption in RA has been explained by the increased osteoclastic activity under the effect of various inflammatory cytokines. Both RANKL-dependent and -independent osteoclastogenesis pathways are thought to play a role in the increased bone turnover in RA. Overproduction of RANKL by a wide range of cells, including osteoblasts, endothelial cells, T cells and B cells is a characteristic feature of RA. RANKL binds to its receptor RANK on the osteoclast precursor, activating their proliferation and stimulating osteoclastogenesis. Human studies have revealed that RANKL plays a crucial role in the pathogenesis of bony erosions and periarticular osteoporosis in RA.
Synovial levels of RANKL positively correlate with disease activity and bone resorption in RA patients. RANKL in synovium is thought to be mainly secreted by B cells, synovial fibroblasts and T cells [37,38]. Moreover, higher serum levels of RANKL were found in patients with high bone resorption markers and low bone mineral density of hips. Also, levels of serum RANKL were able to predict joint destruction [39]. In another recent study, it was suggested that both increased RANKL and decreased OPG in peripheral blood is the main mechanism of osteoporosis in RA [12].

Interestingly, many other cytokines such as TNF-α, IL-1, IL-4, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-17, IL-18, IFN-γ and GM-CSF have variable effects on bone turnover and act via different mechanisms. TNF-α is a key player in RA osteoclastogenesis by both RANKL-dependent and -independent mechanisms. TNF-α-blocking agents have recently been proven to reduce the local and generalized bone loss in RA [40]. Moreover, TNF-α is thought to inhibit bone formation by increasing DKK-1 expression leading to sequestration of LRP5 and LRP6 receptors on the surface of osteoblasts; hence decreasing their binding to Wnt proteins. Blocking the Wnt/β-catenin signaling pathway leads to the inhibition of osteoblast differentiation and stimulation of their apoptosis, resulting in decreased bone formation [41]. IL-1 is capable of increasing bone resorption by increasing the release of MMPs and other degradative products and by promoting osteoclast differentiation and activation [42]. IL-1 can stimulate osteoclasts to secrete RANKL, IL-6 and IL-11; it can also induce bone loss by a RANKL-independent mechanism [43]. Moreover, IL-1, TNF-α and IFN-γ can also suppress bone formation by inhibiting osteoblast collagen formation [44]. IL-6 induces osteoclastogenesis via the activation of T helper cells to secrete RANKL and IL-17 [45], and IL-17 is a major inducer of osteoclastic activity in inflammatory arthritis secreted by Th17 cells [46].

IFN-γ functions as a modulator of bone turnover as it has a dual effect on osteoclasts. IFN-γ can block the formation of osteoclasts directly by inhibiting the differentiation of osteoclast precursors, but can also stimulate osteoclastogenesis indirectly by activating T cells to produce RANKL and TNF-α. It was presumed that the overall effect of IFN-γ is induction of bone loss [47]. However, IFN-γ has recently been found to play a pivotal role in bone formation in vivo. IFN-γ receptor knockout mice developed osteoporosis and suffered from a marked decrease in both osteoblast and osteoclast numbers [48]. By contrast, other cytokines such as IL-4, IL-10, IL-12, IL-13, IL-18 and GM-CSF are protective of bone by either inhibiting osteoclastogenesis, or stimulating bone formation by osteoblasts. IL-4 can suppress bone resorption and promote bone formation through its ability to inhibit the osteoclastogenic cytokines TNF-α, IL-1, IL-6 and IL-11 in RA. Additionally, IL-4 and IL-13 can stimulate osteoblasts and suppress prostaglandin E2 (PGE2) synthesis [49]. IL-10 is secreted by many cells, primarily monocytes and to a lesser extent by lymphocytes, and is known to have an immunoregulatory effect in RA. It is presumed that it may have an anabolic effect on bone turnover by decreasing the production of TNF-α, IL-1, GM-CSF and the expression of HLA class II by monocytes [50]. Moreover, IL-10 is able to suppress the inflammatory effects of Th17 cells and promote the immunoregulatory Treg formation in RA patients, resulting in the inhibition of osteoclast activity [51]. GM-CSF has been thought to inhibit osteoclast formation and activity; nevertheless the results of in vivo studies are conflicting [52]. IL-12 is capable of inhibiting osteoclastogenesis through its ability to stimulate immune cells, particularly T cells and dendritic cells, to secrete IFN-γ [53]. IL-18 is capable of inhibiting osteoclast formation by its ability to stimulate the release of GM-CSF by T helper cells [54]. Additionally, it has recently been reported that IL-18 may inhibit TNF-α-mediated osteoclastogenesis in vivo by a T-cell-independent mechanism [55].

On the other hand, decreased bone formation in RA has been suggested to be mainly due to increased expression of DKK-1. In a mouse model of RA, inhibition of DKK-1 by a neutralizing antibody led to a reversal of bone erosion and resulted in new bone formation although no change in the markers of inflammation was noted [56].

#### The role of T cells

T cells are involved in most of the autoimmune diseases including RA. For many decades, RA was considered to be a T-cell-dependent disease as evidenced by large numbers of CD4+ T cells infiltrating the synovial tissues of RA patients [57]. T cells are activated by antigen-presenting cells and trigger the immune response by secreting a wide range of inflammatory cytokines, and thereby activating the whole immune system. T cells are a major source of RANKL and TNF-α and are therefore capable of regulating
Bone turnover in RA by activating osteoclastogenesis [58]. On the other hand, T cells may have an inhibitory effect on osteoclastogenesis by increasing OPG production by a mechanism that involves increased vitamin D3 activity [59]. Th1 cells produce IFN-γ and IL-2 and activate cell-mediated immune responses, whereas the Th2 subset produces IL-4 and stimulates humoral immunity. Imbalance between these two subsets results in inappropriate production of their respective cytokines and was found to be correlated with disease activity [60]. Despite the inflammatory effects of T cells in RA, there is also a protective subset known as Tregs, which have anti-inflammatory and bone protective effects. They act by regulating both Type 1 and Type 2 helper T cells [61]. Notably, both Tregs and CD8+ T cells have antosteoclastogenic effects [62]. However in RA it has still not been established whether there is a defect in the number or function of Tregs and whether this defect is directly related to RA osteoporosis. Interestingly, TNF-α has been found to suppress the Tregs response and this might be another mechanism by which TNF-blocking agents act to control the disease activity and bone turnover in RA [63]. A third type of helper T cell, Th17 cells, has recently been implicated in RA bone loss. Th17 cells secrete IL-17, which is capable of inducing osteoclastogenesis resulting in bone damage [64]. Additionally, T cells are capable of interacting either directly with osteoblasts and osteoclasts or indirectly via stimulating dendritic cells and B cells [65].

**The role of B cells in bone loss in RA**

Crosstalk between bone cells and B lymphocytes is bidirectional; bone cells can regulate the development and maturation of B cells and B cells can regulate both osteoblastic and osteoclastic activity. The mechanisms that underlie these interactions are only partially understood, as is the precise role of B cells in bone turnover. B cells have the capacity to both stimulate and inhibit bone turnover by direct and indirect mechanisms (Figure 1). Additionally, B cells appear to be capable of affecting bone formation and resorption under different physiological and pathological conditions.

**B cells & cytokines**

Mature B cells secrete a number of different cytokines including RANKL, a key cytokine involved in bone breakdown and its inhibitor OPG. This mechanism works correctly under normal physiological conditions. The bone protective role of B cells is mainly achieved through OPG production. In RA this balance is disturbed by the increased B- and T-cell activity, leading to a marked increase in the production of RANKL by both cells in addition to other proinflammatory cytokines such as TNF-α. This shifts the bone turnover balance towards bone loss. In an RA human model, the cytokine mRNA expression by CD4 and CD8 T cells, B cells, macrophages and neutrophils was evaluated to identify the source of RANKL in the synovial fluid and peripheral blood. B cells appeared to be a major source of RANKL in RA [37]. In addition to the bone specific cytokines mentioned above, other cytokines secreted by B cells can affect bone turnover and can either induce bone formation or bone resorption. TNF-α and IL-6, for example, are pro-osteoclastogenic, while TGF-β, IL-4, IL-10, IL-12 and IL-13 are activators of bone formation. Additionally, B cells secrete IFN-γ, which has both bone resorption and bone formation effects. However, the net effect of these variable B-cell cytokines seems to differ in varying physiological and pathological conditions [66].

**B cells & osteoclasts**

B cells are able to stimulate, both directly and indirectly, the conversion of monocytes to active osteoclasts. More interestingly, studies have shown that osteoclasts and B lymphocytes may both arise from pro-B cells. Pro-B cells from osteopetrotic mice, for example, expressed markers from the B-lymphoid (CD19, CD43 and CD5) and the myeloid (F4/80) lineages. When stimulated with RANKL and M-CSF, these cells could grow into osteoclasts, while they were able to differentiate into B cells when stimulated by IL-7 [67]. Furthermore, B cells have been found capable of trans-differentiating into osteoclasts. Recently it has been found in a murine model that a subset of CD19+ B lymphocytes named B1 cells, can differentiate into mononuclear phagocytes forming osteoclast-like multinucleated giant cells. These cells express RANK and M-CSFR receptor (M-CSFR) and when stimulated with RANKL and M-CSF, these cells transformed into tartrate-resistant acid phosphatase-positive osteoclasts and have osteoclastic properties, leading to the formation of lacunae when allowed to grow on a calcium phosphate analog. Deficiency of B1 cells in these mice resulted in failure of bone resorption. Moreover, reconstitution of these cells resulted in an increase of osteoclastogenesis [68]. In a study of patients with multiple myeloma, the nuclei of malignant...
B cells were found in osteoclasts, which might suggest that myeloma cells can differentiate into osteoclasts, thus explaining the mechanism of increased osteoclastogenesis in these patients [69]. Additionally, deletion of any of the transcription factors PU.1, Ebf-1 and Pax5, which are essential for B-cell development, resulted in marked changes in bone turnover in vivo. The transcription factor PU.1 is a protein encoded by the SPI1 gene; it is a specific factor for gene expression during myeloid and B-lymphoid cell development. Levels of PU.1 positively correlated with osteoclastic differentiation in vitro and deletion of PU.1 in vivo led to the arrest of osteoclast and macrophage differentiation [70]. More recently, reduction in PU.1 activity resulted in impaired B-cell development [71]. Ebf-1 deficiency in mice, another key regulator of B-cell development, led to increased osteoclastogenesis and impaired B-cell development, but despite this there was an overall increased bone mass. The authors explained that the mechanism of increased bone balance was the concomitant increase in the numbers and activity of osteoblasts. However, there is a hypothesis that B-cell depletion may share in this anabolic effect on bone [72]. Pax5 is an essential protein for B-cell differentiation; its deficiency led to arrested B-cell development and maturation [73]. In vivo studies showed that PAX5 deficiency in mice led to loss of B cells and increased bone turnover resulting from a dramatic rise in the numbers of osteoclasts together with a mild reduction in osteoblast numbers. The result was a marked decrease in bone volume, specifically trabecular bone. However, the authors could not confirm whether the resulting osteopenia was due to the decreased osteoblastic activity or the increased osteoclastogenesis, or a combination of both [74]. In summary, there is a close interaction between the development and activity of B cells and osteoclasts. Moreover, they may even share common precursors.

### Effect of B-cell deficiency on bone

A small number of studies have shown that B cells are capable of downregulating osteoclastogenesis and hence are beneficial for bone. In one such study, researchers demonstrated that B cells could inhibit the development of osteoclasts and reduce their lifespan through their ability to produce TGF-β, which has antosteoclastogenic effects [75]. In a murine study, ovariectomy resulted in decreased estrogen levels and increased B-cell formation. These ovariectomized mice had enhanced osteoclastogenesis and reduced bone formation leading to a marked osteoporosis. The effect of increased B cells was thought to have a critical role in the resulting bone

---

**Figure 1. Effect of B cells on bone cells.**

CSF-M: Macrophage-colony stimulating factor; MSC: Mesenchymal stromal cell; OB: Osteoblast; OC: Osteoclast.
The role of B cells in bone turnover in rheumatoid arthritis

**Pathogenesis of bone loss in RA**
- RA-induced osteoporosis is multifactorial with various components of the immune system participating in its pathogenesis, including cytokines, T cells and B cells.

**The role of B cells in bone loss in RA**
- Crosstalk between bone cells and B lymphocytes is bidirectional.
- B lymphocytes have the capacity to both inhibit and stimulate osteoclastogenesis by different mechanisms.
- RANKL and OPG remain the key players in the pathogenesis of osteoporosis in RA but other mediators and cells may also be involved.
- B lymphocytes have a role in bone formation in addition to bone resorption.
- B cells have a significant effect on bone turnover but whether the net effect is towards formation or resorption is still controversial and may well depend on the circumstances.
- B-cell depletion therapies may have a beneficial effect on bone loss.
This study demonstrated the crosstalk between osteoclasts and B cells in the bone marrow.

Financial & competing interests disclosure
JM van Laar has received a research grant, consultancy and speaker fees from Roche. SP Tuck has received speaker fees from Eli Lilly. Roche has not financed this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References
Papers of special note have been highlighted as:
 of interest
 of considerable interest

1 Kviat TK, Glennas A, Knudsdot OG, Smedstad LM, Mowinckel P, Ferre O. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand. J. Rheumatol. 26(6), 412–418 (1997).
2 von Radwitz J. Rheumatoid arthritis ‘costs’ up to £8bn a year. Independent Health News 1931069 (2010).
3 Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J. Rheumatol. 18(6), 804–808 (1991).
4 Rubbert-Roeth A, Finchk A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther. 11(Suppl. 1), S1 (2009).
5 Edwards J, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 359(25), 2572–2581 (2008).
6 Li Y, Toraldo G, Li A et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109(9), 3839–3848 (2007).
7 Li JY, Tawfeek H, Bedi B et al. Ovarectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc. Natl Acad. Sci. USA 108(2), 768–773 (2011).
8 Celik Aydemir AB, Minematsu H, Gardner TR, Kim KO, Ahn JM, Lee FY. Nuclear factor of activated T cells mediates fluid shear stress-and tensile strain-induced Cox2 in human and murine bone cells. Bone 46(1), 167–175 (2010).
9 Kadono Y, Okada F, Perchonock C et al. Strength of TRAF6 signalling determines osteocalcogenesis. EMBO Rep. 6(2), 171–176 (2005).
10 Grassi F, Manfredini C, Cartini L et al. T cell suppression by osteoclasts in vitro. J. Cell Physiol. 226(4), 982–990 (2011).
11 Wheater G, Hogan V, Teng Y et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos. Int. 22(12), 3067–3072 (2011).

This study represents the first proof of the beneficial effect of B cells on bone turnover in humans.

12 Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol. Int. doi:10.1007/s00296-011-2175-5 (2011) (Epub ahead of print).
13 Loder F, Mutschler B, Ray RJ et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190(1), 75–89 (1999).
14 James T, Herzenberg L. Unraveling B-1 progenitors. Curr. Opin. Immunol. 19(2), 150–155 (2007).
15 Morlacchi S, Soldani C, Viola A, Sarukhan A. Self-antigen presentation by mouse B cells results in regulatory T-cell induction rather than anergy or clonal deletion. Blood 118(4), 984–991 (2011).
16 Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13(12), 1583–1595 (2001).
17 Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8–27 (2006).
18 Zhu J, Garrett R, Jung Y et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 109(9), 3706–3712 (2007).
19 Wu JY, Purton LE, Rodda SJ et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gut-dependent signaling pathways. Proc. Natl Acad. Sci. USA 105(44), 16976–16981 (2008).
20 Dorshkind K, Landreth KS. Regulation of B cell differentiation by bone marrow stromal cells. Int. J. Cell Cloning 10(1), 12–17 (1992).
21 Mansour A, Anginol A, Mancini SJ et al. Osteoclast activity modulates B-cell development in the bone marrow. Cell Res. 21(7), 1102–1115 (2011).

This study demonstrated the crosstalk between osteoclasts and B cells in the bone marrow.

22 Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J. Immunol. 177(7), 4481–4487 (2006).
23 Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu. Rev. Immunol. 26, 627–650 (2008).
24 Hirano T, Matsuda T, Turner M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18(11), 1797–1801 (1988).
This study demonstrated that DKK-1 is the major source of RANKL in rheumatoid arthritis and consequently the main drivers of osteoclastogenesis. Receptor activator NF-kB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patient; semi-quantitative and quantitative analysis. Ann. Rheum. Dis. 65(1), 1047–1054 (2004).

**This study showed that B cells are the major source of RANKL and consequently the main drivers of osteoclastogenesis.**

38. Ciotti TN, Smith MD, Weedon H et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthritis, osteoarthritis and from normal patient; semi-quantitative and quantitative analysis. Ann. Rheum. Dis. 65(1), 1047–1054 (2004).

39. Guensens PP, Landew B, Garners P et al. The ratio of circulating osteoprotegerin to receptor activator of nuclear factor-κB ligand (RANKL) in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 54(6), 1772–1777 (2006).

40. Chopin F, Garners P, le Henanff A et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(3), 353–357 (2008).

41. Jilka RL, Weinstein RS, Bellito T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13(5), 793–802 (1998).

42. Bramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxf). 41(9), 972–980 (2002).

43. Kudo O, Sabokbar A, Pocock A, Ionaga I, Fujikawa Y, Athanassou NA. Interleukin-6 and interleukin-11 support human osteoclastogenesis possibly via a T cell-independent mechanism. Bone 42(1), 1–7 (2008).

44. Centrella M, McCarthy TL, Canalis E. Tumor necrosis factor-α inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxynonycholic acid synthesis in osteoblast-enriched bone cell cultures. Endocrinology 123(3), 1442–1448 (1988).

45. Wong PK, Quinn JM, Sims NA et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158–168 (2006).

46. Bertelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J. Immunol. 165(8), 4231–4238 (2000).

60 Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 383(6603), 787–793 (1996).

61 Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum. 43(3), 617–627 (2000).

62 Choi Y, Woo KM, Ko SH et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8 T cells. Eur. J. Immunol. 31(7), 2179–2188 (2001).

* One of the first studies to demonstrate that B cells stimulate bone resorption.

63 van Amelsfort JM, van Rooij JA, Nooredegraaf M et al. Proinflammatory mediator-induced reversal of CD4+CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum. 56(3), 732–742 (2007).

64 Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203(12), 2673–2682 (2006).

65 Choi Y, Kim J. B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesis. Exp. Mol. Med. 35(5), 385–392 (2003).

66 Lund FE. Cytokine-producing B lymphocytes—key regulators of immunity. Curr Opin. Immunol. 20(3), 332–338 (2008).

** This article analyzed the different cytokines secreted by B lymphocytes.

67 Blin-Wakkach C, Wakkach A, Rochet N, Carle GF. Characterization of a novel bipotent hematopoietic progenitor population in normal and osteopetrotic mice. J. Bone Miner. Res. 19(7), 1137–1143 (2004).

68 Pugliese LS, Gonçalves TO, Popi AF, Mariano M, Pesquero JB, Lopes JD. B-1 lymphocytes differentiate into functional osteoclast-like cells. Immunobiology 217(3), 336–344 (2012).

69 Andersen TL, Boissy P, Sondergaard TE et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J. Pathol. 211(1), 10–17 (2007).

70 Tondravi MM, McKercher SR, Anderson K et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386(6620), 81–84 (1997).

71 Houston JB, Kamath MB, Schweitzer BL, Chlon TM, DeKoter RP. Reduction in PU.1 activity results in a block to B-cell development, abnormal myeloid proliferation, and neonatal lethality. Exp. Hematol. 35(7), 1056–1068 (2007).

72 Horowitz MC, Lorenzo JA. B lymphocytes and the skeleton. Ann. N.Y. Acad. Sci. 1117, 82–93 (2007).

73 Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell development and leukemogenesis. Adv. Immunol. 111, 179–206 (2011).

74 Horowitz MC, Xi Y, Pfugh DL et al. Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. J. Immunol. 173(11), 6583–6591 (2004).

75 Weitzmann M, Cenci S, Haug J, Brown C, Martinez-Romero A, Tarin JJ, Cano A. Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. Hum. Reprod. 21, 880–887 (2006).

76 Garcia-Perez MA, Noguera I, Hermenegildo C, Martinez-Romero A, Tarin JJ, Cano A. Expansion of the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. Hum. Reprod. 21, 880–887 (2006).

77 Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kB ligand/osteoprotegerin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15, 1321–1329 (2000).

78 Li Y, Li A, Yang X, Weitzmann M. Ovariectomy-induced bone loss occurs independently of B cells. J. Cell Biochem. 100, 1370–1375 (2007).

79 Manabe N, Kawaguchi H, Chikuda H et al. Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol. 167, 2625–2631 (2001).

80 Neri P, Kumar S, Fulciniti MT et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 13, 5903–5909 (2007).

81 Moura RA, Cascão R, Perpétuo I et al. Cytokine pattern in very early rheumatoid arthritis favors B-cell activation and survival. Rheumatology (Oxf.). 50(2), 278–282 (2011).

82 Khan WN, Alt FW, Gerstein RM et al. Defective B cell development and function in Bk-deficient mice. Immunity 3(3), 283–299 (1995).

83 Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13(18), 2412–2424 (1999).

84 Tsapogas P, Zandi S, Åhsberg J et al. IL-7 mediates Ebf-1–dependent lineage restriction in early lymphoid progenitors. Blood 118(5), 1283–1290 (2011).

85 Szodoray P, Alex P, Frank MB et al. A genome-scale assessment of peripheral blood B cell molecular homeostasis in patients with rheumatoid arthritis. Rheumatology (Oxf.). 45(12), 1466–1476 (2006).

86 Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature 576(6537), 263–267 (1995).

87 Wang JH, Nichogiannopoulou A, Wu L et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5(6), 557–549 (1996).